Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy drugs for cancer and inflammatory diseases.
Its drug-candidates belong to a new class of therapeutic agents and consist of monoclonal antibodies aimed at immune regulatory checkpoints with a unique focus on the innate immunity compartment.
This approach has been validated by two major biopharmaceutical partners : Bristol-Myers Squibb in cancer and Novo Nordisk A/S in inflammation.
